A Study of Atezolizumab in Advanced Solid Tumors

Part of paid clinical trials in New York, New York.

Sponsor
Hoffmann-La Roche
Study ID
NCT02458638
Phase
PHASE2
Status
Completed

Conditions

  • Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The primary efficacy objective for this study is to evaluate non-progression rate (NPR) at 18 weeks in participants with advanced solid tumors treated with atezolizumab, defined as the percentage of participants with complete response (CR), partial response (PR), or stable disease (SD) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1, or according to disease-specific criteria for prostate cancer and malignant pleural mesothelioma.

Key Dates

Start date
Jul 16, 2015
Status verified
May 2021
Primary completion
Apr 4, 2018
Completion
Jul 28, 2020

Study Design

Enrollment
474 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Atezolizumab
    The dose of atezolizumab in this study will be 1200 milligrams (mg) administered by intravenous (IV) infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.

Primary Outcome Measure

Non-progression Rate (NPR) at 18 Weeks [ Time Frame: At Week 18 ]

Locations (5)

FacilityCityStateZIPSite coordinators
Columbia University Medical CenterNew YorkNew York10027-
Memorial Sloan KetteringNew YorkNew York10065-
The Cleveland Clinic FoundationClevelandOhio44195-
Sarah Cannon Cancer Center and Research InstituteNashvilleTennessee37203-
MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in New York, NY

By research site
Columbia University Medical Center· New York, NYMemorial Sloan Kettering· New York, NYThe Cleveland Clinic Foundation· Cleveland, OHSarah Cannon Cancer Center and Research Institute· Nashville, TNMD Anderson Cancer Center· Houston, TX

Related Studies